Loading...

Fady Malik, MD, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address3333 California Street
San Francisco CA 94118
Phone415-353-3817
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco Clinical Fellowship School of Medicine
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1994 Medicine
    University of California, San FranciscoPh.D.1993 Graduate Division (Neuroscience)

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Collibee SE, Bergnes G, Muci A, Browne WF, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik F, Morgans DJ, Morgan BP. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett. 2018 Apr 12; 9(4):354-358. PMID: 29670700.
      View in: PubMed
    2. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik F, Shefner JM. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. PMID: 29402141.
      View in: PubMed
    3. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik F, Shefner JM. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 Jan 01; 75(1):58-64. PMID: 29181534.
      View in: PubMed
    4. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik F. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2017 Nov 18. PMID: 29150952.
      View in: PubMed
    5. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik F, Houdusse A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017 08 04; 8(1):190. PMID: 28775348.
      View in: PubMed
    6. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik F, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 06; 19(6):718-727. PMID: 28345190.
      View in: PubMed
    7. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik F, Westerblad H, Jasper JR. The Ca2+ sensitizer CK-2066260 increases myofibrillar Ca2+ sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017 Mar 01; 595(5):1657-1670. PMID: 27869319.
      View in: PubMed
    8. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik F, Honarpour N. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 12 10; 388(10062):2895-2903. PMID: 27914656.
      View in: PubMed
    9. Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik F, Houdusse AM. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):E7448-E7455. PMID: 27815532.
      View in: PubMed
    10. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik F, Patrick DL, Spertus J, Teerlink JR. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016 Sep 15; 14(1):131. PMID: 27629389.
      View in: PubMed
    11. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik F, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail. 2016 Oct; 4(10):791-804. PMID: 27395351.
      View in: PubMed
    12. Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik F, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 Jul 01; 311(1):L20-8. PMID: 27190061; PMCID: PMC4967190 [Available on 07/01/17].
      View in: PubMed, PubMed Central
    13. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik F, Wasserman SM. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29; 67(12):1444-1455. PMID: 27012405.
      View in: PubMed
    14. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016 Mar; 54(3):217-27. PMID: 26709596; PMCID: PMC4776255.
      View in: PubMed, PubMed Central
    15. Teerlink JR, Malik F, Kass DA. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". Circ Heart Fail. 2015 Nov; 8(6):1141. PMID: 26578671; PMCID: PMC4654674 [Available on 11/01/16].
      View in: PubMed, PubMed Central
    16. Vu T, Ma P, Xiao JJ, Wang YM, Malik F, Chow AT. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov; 55(11):1236-47. PMID: 25951506.
      View in: PubMed
    17. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik F. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr; 12(2):455-60. PMID: 25742919; PMCID: PMC4404445.
      View in: PubMed, PubMed Central
    18. Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik F, Jasper JR. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr; 353(1):159-68. PMID: 25678535.
      View in: PubMed
    19. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik F. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014 Dec; 50(6):925-31. PMID: 24634285; PMCID: PMC4260123.
      View in: PubMed, PubMed Central
    20. Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik F, Wolff AA, Shaburishvili T. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan; 3(1):22-9. PMID: 25453536.
      View in: PubMed
    21. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik F, Hiatt WR. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc Med. 2014 Aug; 19(4):297-306. PMID: 24872402.
      View in: PubMed
    22. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik F, Jasper JR. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. PMID: 24805850; PMCID: PMC4013064.
      View in: PubMed, PubMed Central
    23. Khodjaev SD, Teerlink JR, Malik F. Novel drug mechanisms in development for heart failure. Pflugers Arch. 2014 Jun; 466(6):1219-25. PMID: 24793049.
      View in: PubMed
    24. Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik F, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):863-5. PMID: 24684359; PMCID: PMC4225832.
      View in: PubMed, PubMed Central
    25. Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik F, Tankersley C, Wagner KR. Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve. 2013 Aug; 48(2):279-85. PMID: 23512724.
      View in: PubMed
    26. Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik F, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain. 2013 Jun; 136(Pt 6):1718-31. PMID: 23715096; PMCID: PMC3673460.
      View in: PubMed, PubMed Central
    27. de Winter JM, Buck D, Hidalgo C, Jasper JR, Malik F, Clarke NF, Stienen GJ, Lawlor MW, Beggs AH, Ottenheijm CA, Granzier H. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J Med Genet. 2013 Jun; 50(6):383-92. PMID: 23572184; PMCID: PMC3865762.
      View in: PubMed, PubMed Central
    28. Lee EJ, De Winter JM, Buck D, Jasper JR, Malik F, Labeit S, Ottenheijm CA, Granzier H. Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS One. 2013; 8(2):e55861. PMID: 23437068; PMCID: PMC3577798.
      View in: PubMed, PubMed Central
    29. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. PMID: 22591195.
      View in: PubMed
    30. Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik F, Vatner SF, Shen YT. Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. PLoS One. 2012; 7(5):e36302. PMID: 22563487; PMCID: PMC3341368.
      View in: PubMed, PubMed Central
    31. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu PP, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik F. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19; 18(3):452-5. PMID: 22344294; PMCID: PMC3296825.
      View in: PubMed, PubMed Central
    32. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik F. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20; 378(9792):676-83. PMID: 21856481.
      View in: PubMed
    33. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik F, Wolff AA. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011 Aug 20; 378(9792):667-75. PMID: 21856480.
      View in: PubMed
    34. Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik F, Vatner SF. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct; 339(1):307-12. PMID: 21784887; PMCID: PMC3186291.
      View in: PubMed, PubMed Central
    35. Malik F, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011 Oct; 51(4):454-61. PMID: 21616079.
      View in: PubMed
    36. Malik F, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18; 331(6023):1439-43. PMID: 21415352; PMCID: PMC4090309.
      View in: PubMed, PubMed Central
    37. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik F, Morgans DJ. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Dec 09; 1(9):472-7. PMID: 24900233; PMCID: PMC4007828.
      View in: PubMed, PubMed Central
    38. Shen YT, Malik F, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010 Jul; 3(4):522-7. PMID: 20498236.
      View in: PubMed
    Fady's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (197) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (4) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑